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CLINICAL INQUIRIES
Does tranexamic acid reduce mortality in women with postpartum
hemorrhage?
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EVIDENCE-BASED ANSWER:
Yes. When used in conjunction with the standard of care, 1 g intravenous (IV) tranexamic acid given 1
to 3 hours after delivery is associated with a significant reduction in maternal mortality from
postpartum hemorrhage (PPH) (strength of recommendation: A, randomized controlled trial [RCT]
and Cochrane review).
No known significant risks are associated with the use of tranexamic acid to treat PPH.
EVIDENCE SUMMARY
A 2017 double-blind RCT that included 20,060 women with PPH from 21 countries (the WOMAN trial) found
that the risk of maternal mortality was significantly lower among women who received tranexamic acid as
part of their PPH treatment compared with placebo (1.5% [N = 155] vs 1.9% [N = 191]; P = .045; relative risk
[RR] = 0.81; 95% confidence interval [CI], 0.65-1; number needed to treat [NNT] = 250).
Inclusion criteria were age 16 years or older, postpartum course complicated by hemorrhage of known or
unknown etiology, and a case in which the clinician considered using tranexamic acid in addition to the
standard of care. PPH was defined as > 500 mL blood loss after vaginal delivery, > 1000 mL blood loss after
cesarean section, or blood loss sufficient to produce hemodynamic compromise.
Researchers randomized 10,051 women to the tranexamic acid group and 10,009 to the placebo group.
Women in the experimental group received a 1-g IV injection of tranexamic acid over 10 to 20 minutes. A
second dose was given if bleeding restarted after 30 minutes and within 24 hours of the first dose.
To reduce mortality give tranexamic acid promptly
1
7/1/2020 Does tranexamic acid reduce mortality in women with postpartum hemorrhage? | MDedge Family Medicine
https://www.mdedge.com/familymedicine/article/212069/womens-health/does-tranexamic-acid-reduce-mortality-women-postpartum?channel=27414 2/3
Tranexamic acid reduced mortality most effectively compared with placebo when given within 3 hours of
delivery (1.2% [N = 89] vs 1.7% [N = 127]; P = .008; RR = 0.69; 95% CI 0.52-0.91; NNT = 200). After 3
hours, no significant decrease in mortality occurred. No significant difference in effect was noted between
vaginal and cesarean deliveries nor between uterine atony as the primary cause of hemorrhage and other
causes.
Administering tranexamic acid didn’t reduce the composite primary endpoint of hysterectomy or death from
all causes. Nor did it reduce the secondary endpoints of intrauterine tamponade, embolization, manual
placental extraction, arterial ligation, blood transfusions, or number of units of packed red blood cells. The
tranexamic acid group showed a significant decrease in cases of laparotomy for PPH (0.8% vs 1.3%; P = .002;
RR = 0.64; 95% CI, 0.49-0.85; NNT = 200).
Women who received tranexamic acid vs placebo showed no significant difference in mortality from
pulmonary embolism (0.1% [N = 10] vs 0.1% [N = 11]; P = .82; RR = .9; 95% CI, 0.38-2.13), organ failure ure
(0.3% [N = 25] vs 0.2% [N = 18]; P = .29; RR = 1.38; 95% CI, 0.75-2.53), sepsis (0.2% [N = 15] vs 0.1% [N =
8]; P = .15; RR = 1.87; 95% CI, 0.79-4.4), eclampsia (0.02% [N = 2] vs 0.1% [N = 8]; P = .057; RR = .25; 95%
CI, 0.05-1.17), or other causes (0.2% [N = 20] vs 0.2% [N = 20]; P = .99; RR = 0.99; 95% CI, 0.54-1.85).
Tranexamic acid doesn’t increase the risk of thromboembolism
A 2018 Cochrane review sought more broadly to determine the general effectiveness and safety of
antifibrinolytic drugs in treating primary PPH.  Of 15 RCTs identified, only 3 met the inclusion criteria for
the review, 1 of which was the WOMAN trial (which contributed most of the data in the review). The other
trials were a study conducted in France that recruited 152 women and a study of 200 women in Iran that
contributed only 1 primary outcome—estimated blood loss—to the review. The former study didn’t report any
maternal deaths, and the latter study didn’t look at maternal deaths. The Cochrane review concluded, based
on data from the WOMAN trial, that IV tranexamic acid, if given as early as possible, reduced mortality from
bleeding in women with primary PPH after both vaginal and cesarean delivery and didn’t increase the risk of
thromboembolic events.
Continue to: RECOMMENDATIONS
Evidence-based answers from the Family Physicians Inquiries Network
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